ETFs NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 12/09/2024 BST			5-day change	1st Jan Change
17.33 ^USD	+0.58%		-3.99%	+16.08%

09-03	NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	MT
09-03	Novocure Announces CEO Changes, Effective January 1, 2025	CI

ETFs positioned on NovoCure Limited

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.81%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.71%	0 M€	0.00%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.19%	18 M€	+9.54%	-
ARMOR US EQUITY INDEX ETF - USD	0.08%	9 M€	-.--%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A - EUR HEDGED	0.08%	9 M€	+13.72%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A (EUR) - EUR	0.08%	754 M€	+15.39%
CSIF (IE) MSCI USA ESG LEADERS BLUE UCITS ETF - B - USD	0.04%	2,805 M€	+17.41%
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD	0.04%	833 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.03%	270 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.03%	209 M€	+14.54%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.03%	458 M€	-.--%
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.02%	0 M€	0.00%	-
CSIF (IE) MSCI USA BLUE UCITS ETF B ACC - USD	0.02%	2,627 M€	-.--%	-
AMUNDI MSCI USA ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.02%	1,448 M€	-.--%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.02%	276 M€	+11.40%	-
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD	0.02%	273 M€	+16.86%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.01%	307 M€	+13.93%
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.01%	330 M€	-.--%	-
LYXOR MSCI USA CLIMATE CHANGE UCITS ETF - USD	0.01%	36 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	39 M€	+10.41%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.01%	453 M€	+11.74%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.01%	355 M€	+9.39%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	45 M€	+7.79%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.01%	786 M€	-.--%
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.01%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.01%	284 M€	-.--%

1 2

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,453

Sector

Medical Equipment, Supplies & Distribution

Calendar

15/09/2024 - European Society for Medical Oncology Meeting - Poster No. #459

More about the company